Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (IPN)(adr:IPSEY) (Ipsen), today announced a presentation of data from a
retrospective study on managed Medicaid costs of treating children with
Cerebral Palsy (CP) at the annual meeting of the American Academy of
Cerebral Palsy and Developmental Medicine (AACPDM) on September 13-16,
2017 in Montreal, Canada. This data evaluated recent, large-scale,
landscape studies of the burden of illness for CP patients in the U.S.

Cerebral Palsy is a term for a group of neurological disorders that
appear in infancy or early childhood and affect the part of the brain
that controls muscle movements.
One of the symptoms
associated with CP is spasticity – a condition in which there is an
abnormal increase in muscle tone or stiffness in one or more muscles.

The study objective was to better understand the epidemiology, treatment
patterns, resource utilization and associated costs of children with CP
in the U.S. Managed Medicaid data from a proprietary database covering
15 states and encompassing seven million lives between 2013-2015 was
analyzed, with 3,294 unique cases, which represent patients with CP
(aged 2-20) identified through ICD-9/10 diagnosis codes.

The analysis indicates that 42 percent of children diagnosed with CP did
not receive any of 10 selected therapies commonly used for spasticity
management; these therapies included physical therapy, orthotics, oral
baclofen, botulinum toxin, anti-spasm medication, casting, orthopedic
surgery, baclofen injection, baclofen pumps, and rhizotomies. These
therapies were selected by a group of multidisciplinary researchers and
care team members who determined that these methods were the most
commonly used spasticity management options for CP patients.

The data also showed the average annual cost of treatment for a child
with CP was about 16 times higher than the average cost of treatment for
any child enrolled in Medicaid ($22,383 versus $1,359, respectively)
between the years 2013 and 2015. Annual costs included expenditure from
utilization of pharmacy, medical services, home health, long term care
and hospice. Because CP disease severity cannot be obtained from
diagnosis codes, the study team developed clinical algorithms to assess
the likelihood of ambulation among CP children; 30.5 percent were
identified as likely ambulatory, 33.8 percent as likely non-ambulatory,
and the remainder unknown. Children with CP that were likely
non-ambulatory had average annual costs four times higher than those for
children with CP who were likely ambulatory. There was large variability
in the medical expenditure for children with CP, even for those with the
same ambulatory status. This may be driven in part by regional Medicaid
coverage differences. Limitations of this retrospective study include
incomplete or inaccurate submitted claims. Further research is needed to
understand the specific cost drivers associated with the care of
children with CP.

“This study supports the need for a broader look into the overall
management plans for children living with Cerebral Palsy, including
appropriate treatment options and physical and occupational therapies.
We hope this would also lead to better management of costs for
families,” said David Cox, VP North American Medical, HEOR &
Regulatory Affairs, Ipsen
. “Ipsen is committed to improving the care
of children with lower limb spasticity – especially those with Cerebral
Palsy, the most common motor disability in children.

About Ipsen in North America

Ipsen Biopharmaceuticals, Inc. is the US affiliate of Ipsen, a global
specialty-driven pharmaceutical group. The US head office is located in
Basking Ridge, New Jersey. Ipsen Biopharmaceuticals Canada, Inc. is an
integrated business unit within North America and has its head office
located in Mississauga, Ontario. Ipsen Bioscience, Inc., the Ipsen US
research and development center focused on peptide research in oncology
and endocrinology, is located in Cambridge, Massachusetts. At Ipsen
Bioscience, we focus on creating a highly cooperative and passionate R&D
organization through partnerships, innovation, and continuous learning
to effectively deliver new treatments for patients. At Ipsen, we focus
our resources, investments, and energy on discovering, developing, and
commercializing new therapeutic options for oncologic, neurologic, and
endocrine diseases. For more information on Ipsen in North America,
please visit

About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on
innovation and specialty care. The group develops and commercializes
innovative medicines in three key therapeutic areas – Oncology,
Neurosciences and Rare Diseases. Its commitment to oncology is
exemplified through its growing portfolio of key therapies for prostate
cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic
cancer. Ipsen also has a well-established Consumer Healthcare business.
With total sales close to €1.6 billion in 2016, Ipsen sells more than 20
drugs in over 115 countries, with a direct commercial presence in more
than 30 countries. Ipsen’s R&D is focused on its innovative and
differentiated technological platforms located in the heart of the
leading biotechnological and life sciences hubs (Paris-Saclay, France;
Oxford, UK; Cambridge, US). The Group has about 5,100 employees
worldwide. Ipsen is listed in Paris (IPN) and in the United
States through a Sponsored Level I American Depositary Receipt program
(adr:IPSEY). For more information on Ipsen, visit

Forward Looking Statements

The forward-looking statements, objectives and targets contained herein
are based on the Group’s management strategy, current views and
assumptions. Such statements involve known and unknown risks and
uncertainties that may cause actual results, performance or events to
differ materially from those anticipated herein. All of the above risks
could affect the Group’s future ability to achieve its financial
targets, which were set assuming reasonable macroeconomic conditions
based on the information available today. Use of the words “believes,”
“anticipates” and “expects” and similar expressions are intended to
identify forward-looking statements, including the Group’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document were
prepared without taking into account external growth assumptions and
potential future acquisitions, which may alter these parameters. These
objectives are based on data and assumptions regarded as reasonable by
the Group. These targets depend on conditions or facts likely to happen
in the future, and not exclusively on historical data. Actual results
may depart significantly from these targets given the occurrence of
certain risks and uncertainties, notably the fact that a promising
product in early development phase or clinical trial may end up never
being launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. The Group must face or might face
competition from generic products that might translate into a loss of
market share. Furthermore, the Research and Development process involves
several stages each of which involves the substantial risk that the
Group may fail to achieve its objectives and be forced to abandon its
efforts with regards to a product in which it has invested significant
sums. Therefore, the Group cannot be certain that favorable results
obtained during pre-clinical trials will be confirmed subsequently
during clinical trials, or that the results of clinical trials will be
sufficient to demonstrate the safe and effective nature of the product
concerned. There can be no guarantees a product will receive the
necessary regulatory approvals or that the product will prove to be
commercially successful. If underlying assumptions prove inaccurate or
risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks and
uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation; global
trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approval; the
Group’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the
effectiveness of the Group’s patents and other protections for
innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions. The Group also depends on third
parties to develop and market some of its products which could
potentially generate substantial royalties; these partners could behave
in such ways which could cause damage to the Group’s activities and
financial results. The Group cannot be certain that its partners will
fulfill their obligations. It might be unable to obtain any benefit from
those agreements. A default by any of the Group’s partners could
generate lower revenues than expected. Such situations could have a
negative impact on the Group’s business, financial position or
performance. The Group expressly disclaims any obligation or undertaking
to update or revise any forward looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such statements
are based, unless so required by applicable law. The Group’s business is
subject to the risk factors outlined in its registration documents filed
with the French Autorité des Marchés Financiers.

© 2017 Ipsen Biopharmaceuticals, Inc.
September 2017 DYS-US-002203

View source version on

SOURCE: Ipsen Biopharmaceuticals, Inc.

Marisol Peron, 908-275-6330
Vice President, North
Internal & External Communications
, 646-722-8807

Copyright Business Wire 2017

Go to Source

Ipsen Announces Analysis of Managed Medicaid Data of Children with Cerebral Palsy at Annual Meeting of the American Academy of Cerebral Palsy and Developmental Medicine